Moderna stock edges lower to $56.26 despite U.S. approval of new mRNA flu vaccine

Traders Union
All News
Business & Wealth
Companies
Moderna stock edges lower at $56.26

Highlights

Moderna received FDA approval for mFLUSIVA (mRNA-1010), its new seasonal influenza vaccine for adults aged 50 and above.
The approval was based on unanimous recommendations from the agency's vaccine advisory group, marking a significant regulatory milestone.
Despite muted price action on the news, technicals indicate a split setup with resistance at $58.93 and a weekly expected range of $53.29 to $59.22.

mFLUSIVA gives Moderna access to the large seasonal flu vaccine market and reduces its dependence on declining COVID-19 vaccine sales. The approval also validates the company’s mRNA platform in another major respiratory disease category.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

However, the immediate revenue impact will depend on commercial rollout, demand and competition from established flu vaccines. The unanimous recommendation from the FDA advisory committee had also reduced regulatory uncertainty before the final decision, meaning part of the positive news may already have been priced in.

Moderna stock slips despite FDA approval

Moderna stock fell 1.2% to $56.26 after the approval, showing that investors remain cautious about mFLUSIVA’s near-term commercial contribution. The stock trades below the MA-20 and MA-50 but above the MA-200, leaving the daily setup mixed.

Resistance stands at $58.93. Meanwhile, the Stoch RSI is nearing overbought territory, suggesting limited short-term upside unless the price breaks above this level.

Buyers watched at resistance as long-term trend shows constructive balance

To gauge whether this development is being integrated into trading decisions, traders should focus on new closes relative to $58.93. The strongest sign of market conviction came from a notably wider intraday range, stretching from $55.61 to $59.29, well beyond recent averages. Even so, with a 47% probability of upside and 53% probability of downside within the coming trading week, the expected range is $53.29 to $59.22. A close above $58.93 would indicate buyers are prepared to follow through, while a drop below $52.66 would suggest the move is being unwound. On the weekly chart, the longer-term picture for Moderna stock remains constructive.

Previously it was reported that Moderna began a Phase 1 clinical study for its mRNA-1469 Bundibugyo ebolavirus vaccine candidate in Canada, with technical signals offering a mixed outlook for the stock. The current FDA approval of mFLUSIVA (mRNA-1010) for influenza adds a new regulatory catalyst, and traders should now monitor closes relative to $58.93 as the next key directional level.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.